MetaVia reports 68% placebo‑adjusted liver‑fat reduction in DA‑1726 Phase 1 interim data
+1 new source since this summary was written
MetaVia Inc. presented interim results from Part 3B of its Phase 1 trial of DA‑1726, a dual GLP‑1/glucagon agonist. After 16 weeks, the drug achieved a 68% placebo‑adjusted reduction in liver fat and a 13.5% placebo‑adjusted body‑weight loss in obese adults. HbA1c fell from 5.79% to 5.33%, a 0.24‑percentage‑point placebo‑adjusted drop. Full Part 3A/3B data are slated for Q1 2027 and a 48‑week Phase 2 study in up to 150 MetALD/ALD patients is planned for H2 2027.
Why it matters
The company expects the Phase 2 trial to begin in the second half of 2027, which could move DA‑1726 toward the first approved therapy for MetALD and ALD if results hold. Investors will watch for the Q1 2027 data release as a catalyst for the stock.
Key facts
- 1DA‑1726 produced a 68% placebo‑adjusted reduction in liver fat after 16 weeks (geometric mean ratio 0.32, p<0.001). prnewswire.com
- 2The liver‑fat reduction was observed in 12 treated participants versus 4 on placebo; 10 of 12 treated participants (83%) achieved at least a 30% relative reduction, while none of the placebo participants did. prnewswire.com
- 3All five treated participants with baseline steatosis (MRI‑PDFF ≥5%) fell below 5% by Day 109. prnewswire.com
- 4Body weight decreased by 13.5% placebo‑adjusted (mean loss 12.19 kg, from 98.6 kg to 86.4 kg). investing.com
- 5HbA1c fell from 5.79% to 5.33% in non‑diabetic participants, a 0.24‑percentage‑point placebo‑adjusted reduction. investing.com
- 6Nine of 15 treated participants reported gastrointestinal adverse events; one serious case of severe vomiting occurred, with no new events after Week 9 through Day 109. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.